These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1013 related items for PubMed ID: 12095073

  • 1. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex.
    Dawson LA, Nguyen HQ, Smith DL, Schechter LE.
    J Psychopharmacol; 2002 Jun; 16(2):145-52. PubMed ID: 12095073
    [Abstract] [Full Text] [Related]

  • 2. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex.
    Invernizzi R, Bramante M, Samanin R.
    Pharmacol Biochem Behav; 1996 May; 54(1):143-7. PubMed ID: 8728551
    [Abstract] [Full Text] [Related]

  • 3. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.
    Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I.
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1220-7. PubMed ID: 12183683
    [Abstract] [Full Text] [Related]

  • 4. Effects of chronic fluoxetine treatment in the presence and absence of (+/-)pindolol: a microdialysis study.
    Dawson LA, Nguyen HQ, Smith DI, Schechter LE.
    Br J Pharmacol; 2000 Jun; 130(4):797-804. PubMed ID: 10864885
    [Abstract] [Full Text] [Related]

  • 5. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors.
    Gobert A, Millan MJ.
    Neuropsychopharmacology; 1999 Aug; 21(2):268-84. PubMed ID: 10432475
    [Abstract] [Full Text] [Related]

  • 6. 5-HT1A receptor antagonists neither potentiate nor inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats.
    Moser PC, Sanger DJ.
    Eur J Pharmacol; 1999 May 14; 372(2):127-34. PubMed ID: 10395092
    [Abstract] [Full Text] [Related]

  • 7. Differential effects of coadministration of fluoxetine and WAY-100635 on serotonergic neurotransmission in vivo: sensitivity to sequence of injections.
    Taber MT, Kinney GG, Pieschl RL, Yocca FD, Gribkoff VK.
    Synapse; 2000 Oct 14; 38(1):17-26. PubMed ID: 10941137
    [Abstract] [Full Text] [Related]

  • 8. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
    van Amsterdam C, Seyfried CA.
    Psychopharmacology (Berl); 2014 Jun 14; 231(12):2547-58. PubMed ID: 24419272
    [Abstract] [Full Text] [Related]

  • 9. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
    Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA.
    Eur J Pharmacol; 2005 Mar 07; 510(1-2):49-57. PubMed ID: 15740724
    [Abstract] [Full Text] [Related]

  • 10. The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol.
    Dawson LA, Nguyen HQ.
    Neuropharmacology; 2000 Apr 03; 39(6):1044-52. PubMed ID: 10727715
    [Abstract] [Full Text] [Related]

  • 11. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat.
    De Vry J, Schreiber R, Melon C, Dalmus M, Jentzsch KR.
    Eur Neuropsychopharmacol; 2004 Dec 03; 14(6):487-95. PubMed ID: 15589388
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Synergistic neurochemical and behavioral effects of fluoxetine and 5-HT1A receptor antagonists.
    Trillat AC, Malagié I, Mathe-Allainmat M, Anmella MC, Jacquot C, Langlois M, Gardier AM.
    Eur J Pharmacol; 1998 Sep 18; 357(2-3):179-84. PubMed ID: 9797034
    [Abstract] [Full Text] [Related]

  • 15. Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine.
    Le Poul E, Laaris N, Doucet E, Laporte AM, Hamon M, Lanfumey L.
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Aug 18; 352(2):141-8. PubMed ID: 7477436
    [Abstract] [Full Text] [Related]

  • 16. Chronic fluoxetine-induced desensitization of 5-HT1A and 5-HT1B autoreceptors: regional differences and effects of WAY-100635.
    Newman ME, Shalom G, Ran A, Gur E, Van de Kar LD.
    Eur J Pharmacol; 2004 Feb 13; 486(1):25-30. PubMed ID: 14751404
    [Abstract] [Full Text] [Related]

  • 17. Involvement of glutamate neurotransmission and N-methyl-d-aspartate receptor in the activation of midbrain dopamine neurons by 5-HT1A receptor agonists: an electrophysiological study in the rat.
    Gronier B.
    Neuroscience; 2008 Oct 28; 156(4):995-1004. PubMed ID: 18801415
    [Abstract] [Full Text] [Related]

  • 18. Effects of WAY 100635 and (-)-5-Me-8-OH-DPAT, a novel 5-HT1A receptor antagonist, on 8-OH-DPAT responses.
    Trillat AC, Malagié I, Mathé-Allainmat M, Anmela MC, Jacquot C, Langlois M, Gardier AM.
    Eur J Pharmacol; 1998 Apr 17; 347(1):41-9. PubMed ID: 9650846
    [Abstract] [Full Text] [Related]

  • 19. Desensitization of 5-HT(1A) autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635.
    Hervás I, Vilaró MT, Romero L, Scorza MC, Mengod G, Artigas F.
    Neuropsychopharmacology; 2001 Jan 17; 24(1):11-20. PubMed ID: 11106871
    [Abstract] [Full Text] [Related]

  • 20. Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors.
    Harrison AA, Markou A.
    J Pharmacol Exp Ther; 2001 Apr 17; 297(1):316-25. PubMed ID: 11259559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.